Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

ProMIS Neurosciences stock price, quote, forecast and news

PMN.TO
CA74346M1095
A14WN0

Price

6.00
Today +/-
+0
Today %
+0 %
P

ProMIS Neurosciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the ProMIS Neurosciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the ProMIS Neurosciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the ProMIS Neurosciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze ProMIS Neurosciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

ProMIS Neurosciences Stock Price History

DateProMIS Neurosciences Price
7/21/20236.00 undefined
7/20/20236.24 undefined

ProMIS Neurosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ProMIS Neurosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ProMIS Neurosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ProMIS Neurosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ProMIS Neurosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ProMIS Neurosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ProMIS Neurosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ProMIS Neurosciences’s growth potential.

ProMIS Neurosciences Revenue, EBIT and net profit per share

DateProMIS Neurosciences RevenueProMIS Neurosciences EBITProMIS Neurosciences Net Income
2029e148.44 M undefined0 undefined0 undefined
2028e36.34 M undefined29.46 M undefined0 undefined
2027e0 undefined-8.23 M undefined-10.17 M undefined
2026e0 undefined-17.13 M undefined-20.63 M undefined
2025e0 undefined-22.62 M undefined-17.51 M undefined
2024e0 undefined-17.07 M undefined-13.23 M undefined
2023e0 undefined-21.61 M undefined-16.72 M undefined
20220 undefined-23.38 M undefined-18.06 M undefined
20210 undefined-8.29 M undefined-9.79 M undefined
20200 undefined-5.66 M undefined-5.66 M undefined
20190 undefined-7.4 M undefined-7.4 M undefined
20180 undefined-10.17 M undefined-10.17 M undefined
201710,000 undefined-6.01 M undefined-6.02 M undefined
20160 undefined-3.44 M undefined-3.45 M undefined
201520,000 undefined-1.99 M undefined-2.12 M undefined
2014260,000 undefined-2.14 M undefined-2.14 M undefined
2013150,000 undefined-2.25 M undefined-2.25 M undefined
201250,000 undefined-2.23 M undefined-2.23 M undefined
201190,000 undefined-2.56 M undefined-2.54 M undefined
20101.15 M undefined-3.25 M undefined-3.2 M undefined
2009180,000 undefined-4.86 M undefined-4.86 M undefined
2008240,000 undefined-5.15 M undefined-5.15 M undefined
2007480,000 undefined-7.19 M undefined-7.19 M undefined
2006250,000 undefined-4.23 M undefined-4.23 M undefined
200540,000 undefined-1.49 M undefined-1.97 M undefined
20040 undefined-160,000 undefined-160,000 undefined

ProMIS Neurosciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e2028e2029e
00000010000000000000000036148
-------------------------311.11
--------------------------
00000000000000000-4-160000000
0-1-4-7-5-4-3-2-2-2-2-1-3-6-10-7-5-8-23-21-17-22-17-8290
-------300.00-----------------80.56-
0-1-4-7-5-4-3-2-2-2-2-2-3-6-10-7-5-9-18-16-13-17-20-1000
--300.0075.00-28.57-20.00-25.00-33.33----50.00100.0066.67-30.00-28.5780.00100.00-11.11-18.7530.7717.65-50.00--
419.3131.7641.341.9947.7148.851.2556.7460.6668.02107.97169.9205.78239.19259.8285.65.787.50000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The ProMIS Neurosciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the ProMIS Neurosciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2004200520062007200820092010201120122013201420152016201720182019202020212022
                                     
0.555.3713.858.684.734.42.590.910.040.140.030.940.751.732.431.71.0716.985.91
1080230200501301005050220005050070000
0028040021043014010070130130700000000
0000000000000000000
102013014070140507060805060100330420250130737.32996.68
0.575.4714.499.425.065.12.881.130.220.570.211.070.92.112.852.021.217.716.9
09020058046032013060201010000001004.670.32
0000000000000000000
000000000000000004972
0030000010090908070706050504027.6120.84
0000000000000000000
30000000000000000000
309023058046032013016011010090707060505014081.2893.16
0.65.5614.72105.525.423.011.290.330.670.31.140.972.172.92.071.3417.87
                                     
0.636.6918.0319.219.4723.1923.9724.5525.5827.0828.0730.4732.7137.4745.2249.0352.7400
0.030.742.4134.25.312.114.794.854.995.287.297.887.937.998.078.3568.0479.1
-0.17-2.13-6.37-13.51-18.76-23.76-27.26-29.8-32.03-34.28-36.43-38.55-42-48.02-58.19-65.59-71.25-62.19-0.2
00000.020.023.581.271.382.222.881.391.484.156.138.889.14-0.19-80.25
0000000000000000000
0.495.314.078.694.934.762.40.81-0.220.01-0.20.60.071.531.150.39-1.025.66-1.35
0.070.250.661.30.60.650.610.480.540.470.490.430.780.260.711.460.560.412.98
00000000000000.380.470.220.060.523.44
0000000000.1800000.6301.7800
300000000000120120000000
0000000000000000000
0.10.250.661.30.60.650.610.480.540.650.490.550.90.641.811.682.40.936.41
000000000000000003.910
0000000000000000000
000000000000000007.251.86
0000000000000000011.161.86
0.10.250.661.30.60.650.610.480.540.650.490.550.90.641.811.682.412.098.27
0.595.5514.739.995.535.413.011.290.320.660.291.150.972.172.962.071.3817.756.92
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of ProMIS Neurosciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand ProMIS Neurosciences's financial health and stability.

Assets

ProMIS Neurosciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that ProMIS Neurosciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of ProMIS Neurosciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into ProMIS Neurosciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2004200520062007200820092010201120122013null201420152016201720182019202020212022
0-1-4-7-5-4-3-2-2-2-2-2-2-3-6-10-7-5-9-18
00000000000000000000
00000000000000000000
000000000000000000-15
0000100000000001002-4
00000000000000000000
00000000000000000000
0-1-3-5-4-4-2-2-2-1-1-1-1-2-5-8-6-4-9-17
00000000000000000000
0-5-752030000000000000
0-5-652030000000000000
00000000000000000000
00000000000000000060
0612003001111226853186
0612003001111226953256
--------------------
00000000000000000000
0010-101-1000000000016-11
-0.13-1.64-3.61-6.07-4.24-4.04-2.27-2.33-2.01-1.80-1.37-1.57-2.54-5.7-8.64-6.09-4.46-9.31-17.04
00000000000000000000

ProMIS Neurosciences stock margins

The ProMIS Neurosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProMIS Neurosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProMIS Neurosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ProMIS Neurosciences's sales revenue. A higher gross margin percentage indicates that the ProMIS Neurosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ProMIS Neurosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ProMIS Neurosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ProMIS Neurosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ProMIS Neurosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ProMIS Neurosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ProMIS Neurosciences Margin History

ProMIS Neurosciences Gross marginProMIS Neurosciences Profit marginProMIS Neurosciences EBIT marginProMIS Neurosciences Profit margin
2029e0 %0 %0 %
2028e0 %81.07 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %-60,100.01 %-60,200 %
20160 %0 %0 %
20150 %-9,950 %-10,600 %
20140 %-823.08 %-823.08 %
20130 %-1,500 %-1,500 %
20120 %-4,460 %-4,460 %
20110 %-2,844.44 %-2,822.22 %
20100 %-282.61 %-278.26 %
20090 %-2,700 %-2,700 %
20080 %-2,145.83 %-2,145.83 %
20070 %-1,497.92 %-1,497.92 %
20060 %-1,692 %-1,692 %
20050 %-3,725 %-4,925 %
20040 %0 %0 %

ProMIS Neurosciences Stock Sales Revenue, EBIT, Earnings per Share

The ProMIS Neurosciences earnings per share therefore indicates how much revenue ProMIS Neurosciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ProMIS Neurosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ProMIS Neurosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ProMIS Neurosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ProMIS Neurosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ProMIS Neurosciences Revenue, EBIT and net profit per share

DateProMIS Neurosciences Sales per ShareProMIS Neurosciences EBIT per shareProMIS Neurosciences Earnings per Share
2029e20.63 undefined0 undefined0 undefined
2028e5.05 undefined0 undefined0 undefined
2027e0 undefined0 undefined-1.41 undefined
2026e0 undefined0 undefined-2.87 undefined
2025e0 undefined0 undefined-2.43 undefined
2024e0 undefined0 undefined-1.84 undefined
2023e0 undefined0 undefined-2.32 undefined
20220 undefined-3.12 undefined-2.41 undefined
20210 undefined-1.43 undefined-1.69 undefined
20200 undefined-0.02 undefined-0.02 undefined
20190 undefined-0.03 undefined-0.03 undefined
20180 undefined-0.04 undefined-0.04 undefined
20170 undefined-0.03 undefined-0.03 undefined
20160 undefined-0.02 undefined-0.02 undefined
20150 undefined-0.02 undefined-0.02 undefined
20140 undefined-0.03 undefined-0.03 undefined
20130 undefined-0.04 undefined-0.04 undefined
20120 undefined-0.04 undefined-0.04 undefined
20110 undefined-0.05 undefined-0.05 undefined
20100.02 undefined-0.07 undefined-0.07 undefined
20090 undefined-0.1 undefined-0.1 undefined
20080.01 undefined-0.12 undefined-0.12 undefined
20070.01 undefined-0.17 undefined-0.17 undefined
20060.01 undefined-0.13 undefined-0.13 undefined
20050 undefined-0.08 undefined-0.1 undefined
20040 undefined-0.04 undefined-0.04 undefined

ProMIS Neurosciences business model

ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences is one of the most popular companies on Eulerpool.com.

ProMIS Neurosciences SWOT Analysis

Strengths

ProMIS Neurosciences Inc has several strengths that give them a competitive edge in the market. These include:

  • Strong focus on precision medicine in the field of neurodegenerative diseases
  • Proprietary technology and expertise in identifying unique disease-specific epitopes
  • Strong scientific partnerships and collaborations
  • Robust pipeline of drug candidates targeting various neurological disorders
  • Well-capitalized to fund research and development initiatives

Weaknesses

Despite its strengths, ProMIS Neurosciences Inc also has certain weaknesses that need to be addressed:

  • Relatively small size compared to larger pharmaceutical companies
  • Dependence on successful drug development and commercialization
  • Limited resources for marketing and distribution activities
  • Vulnerability to intellectual property challenges
  • Potential for regulatory hurdles and delays in drug approval

Opportunities

ProMIS Neurosciences Inc can leverage various opportunities to accelerate its growth and success:

  • Increasing prevalence of neurodegenerative diseases globally
  • Rising demand for innovative treatments with superior efficacy and safety profiles
  • Potential collaborations with larger pharmaceutical companies for joint development and commercialization
  • Expansion into emerging markets with unmet medical needs
  • Advancements in technology and research providing potential breakthroughs in the field

Threats

ProMIS Neurosciences Inc should also consider the following threats that may impede its progress:

  • Intense competition from other biotech and pharmaceutical companies in the neurosciences space
  • Stringent regulatory requirements and lengthy approval processes
  • Rapidly evolving market dynamics and potential shifts in treatment paradigms
  • Risks associated with clinical trials, including safety and efficacy concerns
  • Intellectual property infringements by competitors

ProMIS Neurosciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

ProMIS Neurosciences historical P/E ratio, EBIT, and P/S ratio.

ProMIS Neurosciences shares outstanding

The number of shares was ProMIS Neurosciences in 2023 — This indicates how many shares 7.503 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ProMIS Neurosciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ProMIS Neurosciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ProMIS Neurosciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ProMIS Neurosciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ProMIS Neurosciences Stock splits

In ProMIS Neurosciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for ProMIS Neurosciences.

ProMIS Neurosciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2020-0.61 -0.6  (0.99 %)2020 Q3
6/30/2020-0.61 -0.6  (0.99 %)2020 Q2
12/31/2019-0.61 -0.6  (0.99 %)2019 Q4
9/30/2019-0.61 -0.6  (0.99 %)2019 Q3
6/30/2019-0.61 -0.6  (0.99 %)2019 Q2
3/31/2019-0.61 -0.6  (0.99 %)2019 Q1
12/31/2018-0.61 -0.6  (0.99 %)2018 Q4
9/30/2018-0.61 -0.6  (0.99 %)2018 Q3
6/30/2018-0.61 -0.6  (0.99 %)2018 Q2
3/31/2018-0.61 -0.6  (0.99 %)2018 Q1
1
2

ProMIS Neurosciences list of shareholders

%
Name
Stocks
Change
Date
7.09750 % Crocker Mountain LLC510,703510,70310/24/2022
5.01664 % Title 19 Investments LLC360,974360,97410/24/2022
2.36076 % Sclar (Jeremy M.)169,869169,86910/11/2022
2.22263 % Williams (Eugene Warren)159,930-8342/6/2023
1.71586 % Goldstein (Elliot)123,465010/24/2022
1.46395 % Cashman (Neil)105,3392,0162/6/2023
1.38975 % Northeast Financial Consultants Inc100,000012/31/2022
1.08534 % Kirwin (Patrick D)78,0964,0012/6/2023
0.87467 % Wyman (William Williams)62,937-12/6/2023
0.54466 % IEQ Capital LLC39,191012/31/2022
1
2
3

ProMIS Neurosciences Executives and Management Board

Dr. Johanne Kaplan
ProMIS Neurosciences Chief Development Officer
Compensation 664,603
Mr. Gavin Malenfant
ProMIS Neurosciences Chief Operating Officer
Compensation 589,570
Mr. Eugene Williams
ProMIS Neurosciences Executive Chairman of the Board (since 2015)
Compensation 489,379
Mr. Daniel Geffken65
ProMIS Neurosciences Chief Financial Officer
Compensation 180,066
Dr. Neil Cashman
ProMIS Neurosciences Co-Founder, Chief Scientific Officer, Director (since 2004)
Compensation 99,000
1
2
3

ProMIS Neurosciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
JSR Stock
JSR
SupplierCustomer0,51-0,54-0,420,47-0,140,02
1

Most common questions regarding ProMIS Neurosciences

What values and corporate philosophy does ProMIS Neurosciences represent?

ProMIS Neurosciences Inc represents a commitment to advancing precision medicine for neurodegenerative diseases. The company's corporate philosophy centers around leveraging its proprietary technology and expertise to develop novel and specific antibody therapeutics. ProMIS Neurosciences Inc prioritizes the identification of unique targets on misfolded proteins associated with diseases like Alzheimer's, Parkinson's, and ALS. By focusing on these precise targets, the company aims to develop highly selective and effective treatments while minimizing the potential for off-target effects. Through its dedication to precision medicine, ProMIS Neurosciences Inc strives to make a significant impact on the lives of patients suffering from neurodegenerative disorders.

In which countries and regions is ProMIS Neurosciences primarily present?

ProMIS Neurosciences Inc primarily operates in Canada and the United States. The company is headquartered in Toronto, Ontario, Canada, and has a significant presence in various regions across North America. ProMIS Neurosciences is dedicated to developing precision medicine therapies for neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. With a focus on using proprietary computational algorithms and expertise in disease-specific targets, ProMIS Neurosciences aims to address the unmet needs of patients globally. By leveraging its innovative approach, the company is actively advancing the development of novel antibody candidates for neurodegenerative disorders.

What significant milestones has the company ProMIS Neurosciences achieved?

ProMIS Neurosciences Inc has achieved several significant milestones. Firstly, the company has developed unique and innovative precision medicine programs targeting neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS. Furthermore, ProMIS has successfully identified and characterized specific epitope targets on toxic, misfolded proteins associated with these diseases. This allows for the development of highly selective antibody therapeutics to tackle these targets. ProMIS has also successfully generated multiple antibodies, including PMN310, targeting Alzheimer's, which showed a high selectivity for toxic protein aggregates in preclinical studies. These accomplishments highlight ProMIS Neurosciences Inc's dedication to advancing the treatment and understanding of neurodegenerative diseases.

What is the history and background of the company ProMIS Neurosciences?

ProMIS Neurosciences Inc, a leading biotechnology company, specializes in discovering and developing precision therapies for neurodegenerative diseases. Established in 2006, ProMIS focuses on targeting the toxic forms of proteins implicated in diseases like Alzheimer's, amyotrophic lateral sclerosis (ALS), and Parkinson's. By leveraging its unique algorithms and novel antibody discovery platform, the company aims to deliver highly specific and efficacious treatments while minimizing off-target effects. With a commitment to innovation and scientific excellence, ProMIS has amassed a vast portfolio of potential therapeutic candidates. As an industry leader, ProMIS Neurosciences Inc harnesses cutting-edge research to revolutionize neurodegenerative disease treatment.

Who are the main competitors of ProMIS Neurosciences in the market?

The main competitors of ProMIS Neurosciences Inc in the market are Biogen Inc, AC Immune SA, and Eli Lilly and Company.

In which industries is ProMIS Neurosciences primarily active?

ProMIS Neurosciences Inc primarily operates in the biotechnology and healthcare industries.

What is the business model of ProMIS Neurosciences?

ProMIS Neurosciences Inc is a biotechnology company that focuses on the discovery and development of precision therapeutics for neurodegenerative diseases. Their business model revolves around utilizing their proprietary computational algorithms, which accurately predict disease-specific epitopes, to identify and develop novel antibody therapeutics. By specifically targeting and neutralizing toxic oligomers, ProMIS aims to prevent or slow down the progression of diseases like Alzheimer's and ALS. With a strong focus on precision medicine, ProMIS strives to provide tailored treatments that address the root causes of neurodegenerative disorders. Through their innovative approach, ProMIS Neurosciences Inc aims to improve the lives of patients suffering from these debilitating conditions.

What is the P/E ratio of ProMIS Neurosciences 2024?

The ProMIS Neurosciences P/E ratio is -3.4.

What is the P/S ratio of ProMIS Neurosciences 2024?

The ProMIS Neurosciences P/S ratio is 0.

What is the AlleAktien quality score of ProMIS Neurosciences?

The AlleAktien quality score for ProMIS Neurosciences is 5/10.

What is the revenue of ProMIS Neurosciences 2024?

The revenue cannot currently be calculated for ProMIS Neurosciences.

How high is the profit of ProMIS Neurosciences 2024?

The expected ProMIS Neurosciences profit is -13.23 M CAD.

What is the business model of ProMIS Neurosciences

ProMIS Neurosciences Inc is a Canadian biotechnology company specializing in the discovery and development of precision medicines for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (ALS). The company utilizes a unique Precision Medicine platform to identify highly specific therapeutic antibody candidates that bind specifically to the disease-associated proteins of these conditions. Promis Neurosciences has four main business areas: Discovery, Development, Partnerships, and Integrated Solutions. In the Discovery phase, the company identifies specific disease-associated epitopes on the surfaces of proteins involved in neurodegenerative diseases. These epitopes form the basis for the development of molecular tools for the diagnosis, prognosis, monitoring, and treatment of these diseases. The Development phase focuses on advancing the antibody candidates identified by ProMIS Neurosciences in the Discovery phase. The company utilizes state-of-the-art methods in antibody production, optimization, and validation to improve the efficacy and safety of the candidates. Development also includes conducting preclinical studies and preparing for clinical trials to demonstrate the potential therapeutic applications of the antibody candidates. Through Partnerships, ProMIS Neurosciences collaborates with other companies and scientific institutions to validate, optimize, and license its technology platform and antibody candidates. These partnerships allow the company to share resources and knowledge to advance the development of its therapeutic approaches. ProMIS Neurosciences' integrated solution offering includes a range of tailored services for its customers. For example, the company provides specialized assays and test systems to evaluate the efficacy and selectivity of therapeutic antibodies. It also offers diagnostic tests and monitoring platforms for patients affected by neurodegenerative diseases. Additionally, ProMIS Neurosciences provides consultancy services for companies and scientific institutions interested in utilizing the company's Precision Medicine technology platform. ProMIS Neurosciences also offers a range of products for the diagnosis and monitoring of neurodegenerative diseases such as Alzheimer's and Parkinson's. These products include antibody-based assays specifically designed for disease-associated proteins, as well as diagnostic tests for clinical laboratories and for use in preclinical research. Overall, ProMIS Neurosciences provides a comprehensive and integrated solution for the discovery, development, and delivery of precision medicines for the treatment of neurodegenerative diseases. The company utilizes modern technologies and innovative approaches to develop highly specific and safe therapeutic antibodies for these serious conditions.

What is the ProMIS Neurosciences dividend?

ProMIS Neurosciences pays a dividend of 0 CAD distributed over payouts per year.

How often does ProMIS Neurosciences pay dividends?

The dividend cannot currently be calculated for ProMIS Neurosciences or the company does not pay out a dividend.

What is the ProMIS Neurosciences ISIN?

The ISIN of ProMIS Neurosciences is CA74346M1095.

What is the ProMIS Neurosciences WKN?

The WKN of ProMIS Neurosciences is A14WN0.

What is the ProMIS Neurosciences ticker?

The ticker of ProMIS Neurosciences is PMN.TO.

How much dividend does ProMIS Neurosciences pay?

Over the past 12 months, ProMIS Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProMIS Neurosciences is expected to pay a dividend of 0 CAD.

What is the dividend yield of ProMIS Neurosciences?

The current dividend yield of ProMIS Neurosciences is .

When does ProMIS Neurosciences pay dividends?

ProMIS Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProMIS Neurosciences?

ProMIS Neurosciences paid dividends every year for the past 0 years.

What is the dividend of ProMIS Neurosciences?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProMIS Neurosciences located?

ProMIS Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProMIS Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProMIS Neurosciences from 9/9/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did ProMIS Neurosciences pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of ProMIS Neurosciences in the year 2023?

In the year 2023, ProMIS Neurosciences distributed 0 CAD as dividends.

In which currency does ProMIS Neurosciences pay out the dividend?

The dividends of ProMIS Neurosciences are distributed in CAD.

All fundamentals about ProMIS Neurosciences

Our stock analysis for ProMIS Neurosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProMIS Neurosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.